OA11968A - Purine derivatives. - Google Patents

Purine derivatives. Download PDF

Info

Publication number
OA11968A
OA11968A OA1200100332A OA1200100332A OA11968A OA 11968 A OA11968 A OA 11968A OA 1200100332 A OA1200100332 A OA 1200100332A OA 1200100332 A OA1200100332 A OA 1200100332A OA 11968 A OA11968 A OA 11968A
Authority
OA
OAPI
Prior art keywords
alkyl
compound
formula
phenyl
purine
Prior art date
Application number
OA1200100332A
Other languages
English (en)
Inventor
Simon John Mantell
Sandra Marina Monaghan
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of OA11968A publication Critical patent/OA11968A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/167—Purine radicals with ribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Communicable Diseases (AREA)

Claims (34)

  1. 77 1 1968 * CLAIMS
    or a pharmaceutically acceptable sait or solvaté thereof, wherein R1 is hydrogen or C^Cg alkyl optionally substituted by 1 or 2substituents each independently selected from phenyl and naphthyl, saidphenyl and naphthyl being optionally substituted by Ο<Οβ alkyl, Ο,-Cg alkoxy,halo or cyano; Rz is H or C^Cg alkyl; A is CrCs alkylene; R3 is (i) hydrogeh, C,-C6 alkyl, -COOR4, -CN, -CONR4R4, C3-C8 cycloalkyl,phenyl or naphthyl, said C3-C8 cycloalkyl, phenyl and naphthyl being optionallysubstituted by CrC„ alkyl, phenyl, C,-Ce alkoxyiC^CgJalkyl, R4R4N(C1-Ce)alkyl,halo(CrCe)alkyl, fiuoro(C.,-C6)alkoxy, C2-C5 alkanoyl, halo, -OR4, cyano, -COOR4, C3-C8 cycloalkyl, -S(O)mRs, -NR4R4, -SO2NR4R4, -CONR4R4, -NR4CORSor-NR4SO2R5, or (ii) when A is C2-C8 alkylene, -NR4R4, -OR4, -OCOR®, -SO2R5, -SO2NR4R4or-NR4COR5, or (iii) a C-linked, 4- to 11-membered ring, mono- or bicyclic, heterocyclehaving either from 1 to 4 ring nitrogen atom(s), or 1 or 2 nitrogen and 1 oxygenor 1 sulphur ring atoms, being optionally C-substituted by oxo, C5-C8 alkoxy (C,- 78 11968 * C8)alkyl, R6R6N(C1-C6)alkyl, halo(C,-C6)alkyl, fluoro(C1”Ce)alkoxy, fluoro(C2-Cs)alkanoyi, halo, cyano, -OR®, R7, -COR®, -NR8R6, -COOR8, -S(O)roR7,-SO2NR®R6, -CONR6R8, -NR8SOZR7 or-NR8COR7 and optionally N-substitutedby C,-Ce alkoxy(C.,-CB)alkyl, R8R6N(C2-Ce)alkyl, haio(C,-Ce)alkyI, fluoro(C2-C5)alkanoyl, R7, -COR®, -COOR7, -SO2R7, -SO2NR®R® or-CONReR®,or (iv) when A is C2-Ce alkylene, N-linked azetidinyl, pyrrolidinyl, piperidinyl,piperazinyl, homopiperazinyl or morpholinyi, each being optionally C-substitutedby C^Cg alkyl, phenyl, C^Cg alkoxy(C1-C6)alkyl, R4R4N(C1-Ce)alkyl, halo(C1-Cs)alkyl, fIuoro(C1-C6)alkoxy, C2-C5 alkanoyl, halo, -OR4, cyarto, -COOR4, C3-C8cycloalkyl, -S(O)mR5, -NR4R4, -SO2NR4R4, -C0NR4R4, -NR4CORS or-NR4SO2R5,and said piperazinyl and homopiperazinyl being optionally N-substituted by CrC6 alkyl, phenyl, C^Cg alkoxy(C2-Ce)alkyl, R4R4N(C2-Ce)alkyl, fluoro^-CJalkyl,C2-C5 alkanoyl, -COOR®, C3-C8 cycloalkyl, -SO2R5, -SO2NR4R4 or -CONR4R4; R4 is H, C,-Ce alkyl, C3-C8 cycloalkyl or phenyl; R5 is C,-Ce alkyl, C3-C8 cycloalkyl or phenyl; R® is H, C^Cg alkyl, C3-C8 cycloalkyl, phenyl, naphthyl or het; R7 is C^Cg alkyl, C3-C8 cycloalkyl, phenyl, naphthyl or het; m is 0,1 or 2; and "het”, used in the définitions of R8 and R7, means C-linked pyrrolyl, imidazolyl,triazolyl, thienyl, furyl, thiazolyl, oxazolyl, thiadiazolyl, oxadiazolyl, pyridinyl,pyrimidinyi, pyridazinyl, pyrazinyl, indolyi, isoindolyl, quinoiinyl, isoquinolinyl,benzimidazolyl, quinazolinyl, phthalazinyi, benzoxazoiyl or quinoxalinyl, eachbeing optionally substituted by C,-Ce alkyl, Ο,-Cg alkoxy, cyano or halo.
  2. 2. A compound as claimed in claim 1 wherein R1 is C^Cg alkyl optionallysubstituted by 1 or 2 phenyl substituents.
  3. 3. A compound as claimed in claim 2 wherein R1 is 2,2-diphenylethyl.
  4. 4. A compound as claimed in any one of the preceding daims wherein R2 is H. 1196 8 79
  5. 5. A compound as claimed in any one of the preceding daims wherein A is C,-C4 alkylene.
  6. 6. A compound as claimed in claim 5 wherein A is methylene, 1,2-ethylene or 1,3-propylene.
  7. 7. A compound as claimed în daim 6 wherein A is 1,2-ethylene.
  8. 8. A compound as claimed in any one of the preceding daims wherein R3 isphenyi optfonaiiy substituted as defined for this définition in claim 1; or, when Ais C2-CB alkylene, R3 is -NR4R4 wherein R4 is as defined in claim 1; or R3 is a C-iinked, 5- to 7-membered ring monocyclic heterocycle having eitherfrom 1 to 4ring nitragen atom(s) or 1 or 2 nitrogen and 1 oxygen or 1 sulphur ring atoms,optionally substituted as defined for this définition in daim 1 ; or, when A is C2-C6 alkylene, R3 is N-linked pyrroiidinyi, piperidinyl or morphoiinyl, each beingoptionally C-substituted as defined for this définition in daim 1.
  9. 9. A compound as claimed in daim 8 wherein R3 is phenyi; or, when A is C2-Cealkylene, R3 is -NR4R4 wherein R4 is C,-C8 alkyi; or, R3 is a C-linked, 5- or 6-membered ring monocyclic aromatic heterocyde having from 1 to 4 ringnitrogen atom(s), optionally substituted as defined for this définition in daim 1:or, when A is C2-Ce alkylene, R3 is N-linked pyrroiidinyi, piperidinyl ormorphoiinyl, each being optionally C-substituted by CrCe alkyi or-OR4 whereinR4is as previously defined in claim 1.
  10. 10. A compound as claimed in claim 9 wherein R3 is phenyi; or, when A is C2-C„alkylene, R3 is -N(CH3)2; or R3 is C-iinked pyridinyl optionally substituted by —OR6, R7, CrCe alkoxy(C,-C6)alkyl, ReR6N(C,-Ce)alkyl or -NR6R® wherein Re andR7 are as previously defined in claim 1; or when A is C2-C6 alkylene, R3 ispyrrolidin-1-yl, piperidin-1-yl, 4-isopropylpiperidin-1-yl or morpholin-4-yI. 1196 8 80
  11. 11. A compound as ciaimed in ciaim 10 wherein R3 is phenyi; or, when A is C2-Ce aikyiene, R3 is -N(CH3)2; or R3 is 2-pyridinyi; or when A is C2-CB alkyiene, R3is pyrrolidin-1-yl, piperidin-1-yl, 4-isopropylpiperidin-1-yl or morpholin-4-yl.
  12. 12. A compound as ciaimed in ciaim 11 wherein, when A is C2-C„ alkyiene, R3 ispiperidin-1-yl.
  13. 13. A compound as ciaimed in any one of daims 1 to 4 wherein -A-R3isphenethyl, 2-(dimethylamino)ethyl, 2-pyridinylmethyi, 2-(2-pyridinyl)ethyl, 3-(1-pyrrolidinyQpropyi, 2-(1-piperidinyl)ethyi, 2-(4-isopropyi-1-piperidinyl)ethyl or 2-{4-morpholinyl)ethyi.
  14. 14. A compound as ciaimed in ciaim 13 wherein -A-R3 is 2-(1-piperidinyl)ethyl.
  15. 15. A compound as ciaimed in daim 1 which is selected from the groupconsisting of 9-((2/^,3ft,4S,5R)-3,4~dihydroxy-5-(hydroxymethyl)tetrafiydro-2-furanyl]-6-[(2,2-diphenylethyl)amino]-/V-[2-(1-piperidinyl)ethyl]-9H-purine-2-carboxamide; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxyrnethyl)tetrahydro-2-furanyl]-6-[(2,2- diphenylethyl)amino}-N-phenethyl-9H-purine-2-carboxamide; 9-[(2R,3R,4S,5/?)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanylJ-6-[(2,2- diphenylethyl)aminoî-/V-(2-(4-isopropyl-1-piperidinyl)ethyi]-9K-purine-2- carboxamide; 9-[(2R,3R,4S,5R)-314-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2- diphenylethy!)amino]-N-[3-(1-pyrroiidinyl)propyl]-9H-purine-2-carboxarnide; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2- diphenyIethyi)amino]-W-[2-(4-morpholinyi)ethylî-9H-purine-2-carboxamide; 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2- diphenylethyl)amino]-A/-(2-pyridinyimethyi)-9H-purine-2-carboxamide; 81 11968 9-[(2/?,3R4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furany!]-6-{(2,2-diphenylethyl)amino]-N-[2-(2-pyridinyl)ethyl]-9H-purine-2-carboxamide; and9-[(2R, 3R,4S,5R)-3,4-dihydroxy-5-{hydroxymethyl)tetrahyd ro-2-furanylj-/V-[2-(dimethylamino)ethyl]-6-[(2,2-diphenylethyl)amino]-9H-purine-2-carboxamide:and the pharmaceutically acceptable salts and solvatés thereof.
  16. 16. A compound as claimed in claim 1 which is 9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-{hydroxymethyl)tetrahydro-2-furanyl]-6-[(2,2-diphenylethyl)aminoî-A/-[2-(1-piperidinyl)ethyl]-9H-purine-2-carboxamide, or a pharmaceuticallyacceptable sait or solvaté thereof.
  17. 17. A compound as claimed in daim 1 wherein R1 is hydrogen or C, -Ceaikyl substituted by 1 or 2 substituents eachindependently selected from phenyl and naphthyi; R2 is hydrogen or CrC6 alkyl; A is C,-Ce aikylene; and R3 is phenyl, naphthyi, C3-C8 cycloalkyl, azetidinyl, pyrrolidinyl, piperidinyi,amino, -NH(C,-C6 alkyi) or -N(C,-C6 aîkyl)2, said phenyl, naphthyi, C3-Cacycloalkyl, azetidinyl, pyrrolidinyl and piperidinyi being optionally substituted byone or more substituents each independently selected from CrC6 alkyl, C,-CBalkoxy, haio(C,-Ce)alkyl, halo and cyano: with the proviso that when R3 is N-linked, optionally substituted-azetidinyl, -pyrrolidinyl or -piperidinyi, or is amino, -NHCC^Cg alkyl) or -N(C1-Ce alkyl)2, A isC2-Ce aikylene.
  18. 18. A pharmaceuticai composition including a compound of the formula (I) or apharmaceutically acceptable sait or solvaté thereof, as claimed in any one ofthe preceding daims, together with a pharmaceutically acceptable excipient,diluent or carrier. 1196 8 82
  19. 19. A compound of the formula (I) or a pharmaceuticaily acceptable sait,solvaté or composition thereof, as claimed in any one claims 1 to 17 and 18,respectively, for use as a médicament.
  20. 20. The use of a compound of the formula (I) or of a pharmaceuticailyacceptable sait, solvaté or composition thereof, as claimed in any one daims 1to 17 and 18, respectively, for the manufacture of a médicament having A2areceptor agonist activity.
  21. 21. The use of a compound of the formula (I) or of a pharmaceuticailyacceptable sait, solvaté or composition thereof, as daimed in any one claims 1to 17 and 18, respectively, for the manufacture of an anti-inflammatory agent.
  22. 22. The use of a compound of the formula (I) or of a pharmaceuticailyacceptable sait, solvaté or composition thereof, as claimed in any one daims 1to 17 and 18, respectively, for the manufacture of a médicament for thetreatment of a respiratory disease.
  23. 23. Use as claimed in daim 22 where the disease is seiected from the groupconsisting of adult respiratory distress syndrome (ARDS), bronchitis, chronicbronchitis, chronic obstructive pulmonary disease, cystic fibrosis, asthma,emphysema, bronchiectasis, chronic sinusitis and rhinitis.
  24. 24. The use of a compound of the formula (I) or of a pharmaceuticailyacceptable sait, solvaté or composition thereof, as daimed in any one claims 1to 17 and 18, respectively, for the manufacture of a médicament for thetreatment of septic shock, male erectiie dysfunction, hypertension, stroke,epiiepsy, cérébral ischaemia, peripheral vascular disease, post-ischaemicreperfusion injury, diabètes, rheumatoid arthritis, multiple sclerosis, psoriasis,dermatitis, aliergic dermatitis, eczema, uicerative colitis, Crohns disease,inflammatory bowei disease, Heliobacter pylori gastritis, non-Heliobacterpylori 83 gastritis, non-steroidal anti-inflammatory drug-induced damage to the gastro- intestinal tract or a psychotic disorder, or for wound healing. 11968
  25. 25. A process for the préparation of a compound of the formula (I), or apharmaceutically acceptable sait thereof, as claimed in daim 1 comprising a) aminocarbonyiation reaction of a compound of the formula:
    wherein R1 is defined in daim 1 and X is a leaving group such as bromo, iodo,16 Sn(C,-C12 alkyl)3 or CF3SO2O-, with a compound of the formula: R2NH-A-R3 (III) 20 wherein A, R2 and R3 are as defined in claim 1, in the presence of carbonmonoxide and a suitabie coupling catalyst; or b) deprotection of a compound of the formula: 25 119 6 8 84.
    wherein A, R1, R2 and R3are as defined in claim 1 and R8 and R9, when takenseparately, are protecting groups, or, when taken together, are a protecting 5 group; or c) deprotection of a compound of the formula:
    10 wherein A, R1, R2 and R3are as defined in claim 1 and R”, R12 and R13, takenseparately, are protecting groups, or R11 is a protecting group and R12 and R13,taken together, are a protecting group: or 15 d) reaction of a compound of the formula: 85. 1196 8
    wherein R1 is as defined in daim 1 and R17 is H or an ester-forming group, witha compound of the formula (III) as defined in part (a), and, where R17 is H, in the 5 presence of a peptide coupling agent: any one of said pracesses being optionally followed by conversion to apharmaceutically acceptable sait thereof. 10 26. A compound of the formula:
    wherein X is a leaving group such as bromo, iodo, -SnfC^C^ alkyl)3 or15 CF3SO2O-, with the proviso that when X is bromo or iodo, R1 is not H; or 1196 8 86.
    wherein R8 and R9, when taken separately, are protecting groups, or, whentaken together, are a protecting group; or
    wherein R8 and R9, when taken separately, are protecting groups, or, whentaken together, are a protecting group, and R10 is a protecting group; or 10 87. 119 6 8
    wherein R8 and R9, when taken separately, are protecting groups, or, whentaken together, are a protecting group, and R10 is a protecting group, with theproviso when R1 is H, that R8, R9 and R10 are not each t-butyldimethyisilyl or 5 acetyl; or
    wherein R11, R12 and R13, taken separately, are protecting groups, or R11 is aprotecting group and R12 and R13, taken together, are a protecting group; or 10
    o (XIII) ; or 11968 88.
    wherein R” is a protecting group; or
    5 wherein R14 is a protecting group: and A, R1, R2 and R3 are as defined in claim 1.
  26. 27. A compound of the formula:
    (XXIV) : or 11968 89.
    wherein R17 is H or an ester-forming group; or
    wherein R11, R12 and R13, taken separately, are protecting groupe, or R11 is aprotecting group and R12 and R13, taken together, are a protecting group, andR17 is an ester-forming group ; or
    wherein R17 is an ester-forming group; or 11968 90.
    wherein R14is a protecting group and R15 is 0,-04 alkyl: and R1 is C,-Ce alkyl optionally substituted by 1 or 2 substituants eachindependently selected from phenyl and naphthyi, said phenyl and naphthylbeing optionally substituted by 0,-0β alkyl, Ο,-Οθ alkoxy, halo or cyano.
  27. 28. A compound as claimed in any one of daims 26 and 27 wherein R1 is 2,2-diphenylethyl, R2 is H and/or-A-R3 is 2-(1-piperidinyl)ethyl.
  28. 29. A compound of the formula (II) as claimed in daim 26 wherein X is iodo.
  29. 30. A compound of the formula (VI), (IX) or (X) as claimed in daim 26 whereinR8 and R9 when taken seperately are each acetyl or benzoyl or when takentogether are 1,1-dimethylmethylene.
  30. 31. A compound of the formula (IX) or (X) as claimed in claim 26 wherein R10 isa silyl protecting group, preferably t-butyldimethylsilyl ort-butyidiphenylsilyl.
  31. 32. A compound of the formula (XII) as claimed in daim 26 wherein R11, R12 andR13 when taken seperately are each acetyl or benzoyl, or R12 and R13 whentaken together are 1,1-dimethylmethylene.
  32. 33. A compound of the formula (XXI) or (XXII) as claimed in claim 26 or (XX)as claimed in claim 27, wherein R14is tetrahydro-2H-pyran-2-yl. 11968 91.
  33. 34. A compound of the formula (XXV), (XXVI) or (XXVII) as claimed in claim 27wherein R17 is aikyl, preferably methyl or ethyl.
  34. 35. A compound of the formula (XXVI) as claimed in claim 27 wherein R11, R125 and R13 when taken seperately are each acetyl or benzoyl, or R12 and R13 when taken together are 1,1-dimethylmethylene.
OA1200100332A 1999-06-15 2000-06-13 Purine derivatives. OA11968A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9913932.1A GB9913932D0 (en) 1999-06-15 1999-06-15 Purine derivatives

Publications (1)

Publication Number Publication Date
OA11968A true OA11968A (en) 2006-04-17

Family

ID=10855403

Family Applications (1)

Application Number Title Priority Date Filing Date
OA1200100332A OA11968A (en) 1999-06-15 2000-06-13 Purine derivatives.

Country Status (38)

Country Link
US (2) US6900309B1 (fr)
EP (1) EP1185542A2 (fr)
JP (1) JP2003502339A (fr)
KR (1) KR20020010707A (fr)
CN (1) CN1179970C (fr)
AP (1) AP2001002361A0 (fr)
AR (1) AR024345A1 (fr)
AU (1) AU764106B2 (fr)
BG (1) BG106289A (fr)
BR (1) BR0011705A (fr)
CA (1) CA2379786C (fr)
CZ (1) CZ20014397A3 (fr)
DZ (1) DZ3168A1 (fr)
EA (1) EA004861B1 (fr)
EC (1) ECSP003531A (fr)
EE (1) EE200100681A (fr)
GB (1) GB9913932D0 (fr)
GT (1) GT200000096A (fr)
HN (1) HN2000000097A (fr)
HR (1) HRP20010927A2 (fr)
HU (1) HUP0203419A3 (fr)
IL (1) IL147098A0 (fr)
IS (1) IS6196A (fr)
MA (1) MA26799A1 (fr)
MX (1) MXPA01013094A (fr)
NO (1) NO20016109L (fr)
NZ (1) NZ516094A (fr)
OA (1) OA11968A (fr)
PA (1) PA8497001A1 (fr)
PE (1) PE20010430A1 (fr)
PL (1) PL354367A1 (fr)
SK (1) SK18192001A3 (fr)
SV (1) SV2001000100A (fr)
TN (1) TNSN00133A1 (fr)
TR (1) TR200103607T2 (fr)
UY (1) UY26204A1 (fr)
WO (1) WO2000077018A2 (fr)
ZA (1) ZA200110208B (fr)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264826T3 (es) * 1998-10-16 2007-01-16 Pfizer Inc. Derivados de adenina.
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB9924361D0 (en) 1999-10-14 1999-12-15 Pfizer Ltd Purine derivatives
GB0003960D0 (en) 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives
TWI227240B (en) * 2000-06-06 2005-02-01 Pfizer 2-aminocarbonyl-9H-purine derivatives
US6753322B2 (en) * 2000-06-06 2004-06-22 Pfizer Inc 2-aminocarbonyl-9H-purine derivatives
US6921753B2 (en) 2000-06-27 2005-07-26 Pfizer Inc Purine derivatives
GB0015727D0 (en) * 2000-06-27 2000-08-16 Pfizer Ltd Purine derivatives
GB0022695D0 (en) 2000-09-15 2000-11-01 Pfizer Ltd Purine Derivatives
GB0104555D0 (en) * 2001-02-23 2001-04-11 Glaxo Group Ltd New Therapeutic method
WO2002072067A2 (fr) * 2001-03-12 2002-09-19 Glaxo Group Limited Formulation aerosol pharmaceutique
GB0129273D0 (en) * 2001-12-06 2002-01-23 Pfizer Ltd Crystalline drug form
GB0129397D0 (en) * 2001-12-07 2002-01-30 Pfizer Ltd Pharmaceutical combination
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
AR044519A1 (es) 2003-05-02 2005-09-14 Novartis Ag Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
WO2005019238A1 (fr) * 2003-08-22 2005-03-03 Meiji Seika Kaisha, Ltd. Nouveaux derives d'azalide et d'azalactam et procede permettant de produire ces derives
JP2005132767A (ja) * 2003-10-30 2005-05-26 Sumitomo Chemical Co Ltd プリン化合物の製造方法
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
TWI346109B (en) 2004-04-30 2011-08-01 Otsuka Pharma Co Ltd 4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
GB0500785D0 (en) * 2005-01-14 2005-02-23 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
EP2532677A1 (fr) 2005-10-21 2012-12-12 Novartis AG Anticorps humains dirigés contre l'IL -13 et utilisations thérapeutiques
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2640089C (fr) * 2006-02-03 2013-07-23 Cv Therapeutics, Inc. Procede de preparation d'un agoniste de recepteur a2a-adenosine et ses polymorphes
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
JP5584138B2 (ja) 2008-01-11 2014-09-03 ノバルティス アーゲー キナーゼ阻害剤としてのピリミジン類
ES2396023T3 (es) 2009-01-29 2013-02-18 Novartis Ag Bencimidazoles sustituidos para el tratamiento de astrocitomas
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
BR112012003262A8 (pt) 2009-08-12 2016-05-17 Novartis Ag compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
UA111579C2 (uk) 2009-08-17 2016-05-25 Інтеллікіне Ллк ГЕТЕРОЦИКЛІЧНІ ПОХІДНІ 2-АМІНОБЕНЗО[d]ОКСАЗОЛУ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЇХ ОСНОВІ ТА ЇХ ЗАСТОСУВАННЯ ДЛЯ ЛІКУВАННЯ ЗАХВОРЮВАННЯ, ПОВ'АНОГО З РІ3-КІНАЗОЮ
IN2012DN01453A (fr) 2009-08-20 2015-06-05 Novartis Ag
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr) 2010-09-09 2012-03-15 Irm Llc Composés et compositions comme inhibiteurs de trk
WO2012107500A1 (fr) 2011-02-10 2012-08-16 Novartis Ag Composés de [1, 2, 4] triazolo [4, 3 -b] pyridazine en tant qu'inhibiteurs de la tyrosine kinase c-met
WO2012116237A2 (fr) 2011-02-23 2012-08-30 Intellikine, Llc Composés hétérocycliques et leurs utilisations
BR112013021638A2 (pt) 2011-02-25 2016-08-02 Irm Llc "compostos inibidores de trk, seu uso e composições que os compreendem"
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
MX371119B (es) 2012-04-03 2020-01-17 Novartis Ag Productos de combinacion con los inhibidores de cinasa de tirosina y su uso.
HK1219421A1 (zh) 2013-03-15 2017-04-07 因特利凯有限责任公司 激酶抑制剂的组合及其用途
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Mdm2抑制劑與BRAF抑制劑之組合及其用途
WO2016011658A1 (fr) 2014-07-25 2016-01-28 Novartis Ag Polythérapie
US10195208B2 (en) 2014-07-31 2019-02-05 Novartis Ag Combination therapy
EP3801069A4 (fr) 2018-06-01 2022-03-16 Cornell University Polythérapie pour maladie ou trouble associé à pi3k
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5536419A (en) 1978-09-08 1980-03-14 Yamasa Shoyu Co Ltd 2-substituted adenosine derivative and its preparation
JPS55153789A (en) * 1979-04-11 1980-11-29 Sankyo Co Ltd Penem-3-carboxylic acid derivative and its preparation
JPS55153798A (en) * 1979-05-18 1980-11-29 Kikkoman Corp Novel 2-substituted-adenosine 3',5'-cyclic phosphate and its preparation
JPH0313934A (ja) * 1989-06-12 1991-01-22 Konica Corp ハロゲン化銀写真感光材料
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5705491A (en) 1992-10-27 1998-01-06 Nippon Zoki Pharmaceutical Co., Ltd. Adenosine deaminase inhibitor
DK155292D0 (da) 1992-12-23 1992-12-23 Novo Nordisk As Kemiske forbindelser, deres fremstilling og anvendelse
JP3362291B2 (ja) * 1993-10-06 2003-01-07 コニカ株式会社 ハロゲン化銀写真感光材料及び画像形成方法
EP1366777B1 (fr) * 1995-04-14 2005-06-15 SmithKline Beecham Corporation Inhalateur doseur de salmétérol
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
ZA9810490B (en) 1997-12-03 1999-05-20 Dainippon Pharmaceutical Co 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
RU2258071C2 (ru) 1999-05-24 2005-08-10 Юниверсити Оф Вирджиния Пэйтент Фаундейшн Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
JP2003502339A (ja) 2003-01-21
IS6196A (is) 2001-12-11
EA004861B1 (ru) 2004-08-26
EP1185542A2 (fr) 2002-03-13
BG106289A (en) 2002-09-30
HK1047111A1 (en) 2003-02-07
US20050124574A1 (en) 2005-06-09
SK18192001A3 (sk) 2003-04-01
AU764106B2 (en) 2003-08-07
HUP0203419A3 (en) 2005-02-28
SV2001000100A (es) 2001-11-08
MXPA01013094A (es) 2002-06-04
KR20020010707A (ko) 2002-02-04
CN1374966A (zh) 2002-10-16
IL147098A0 (en) 2002-08-14
WO2000077018A3 (fr) 2001-12-06
US6900309B1 (en) 2005-05-31
HN2000000097A (es) 2001-03-14
ECSP003531A (es) 2002-01-25
CA2379786C (fr) 2006-11-28
NZ516094A (en) 2004-07-30
CN1179970C (zh) 2004-12-15
AR024345A1 (es) 2002-10-02
HRP20010927A2 (en) 2003-04-30
BR0011705A (pt) 2002-03-26
CA2379786A1 (fr) 2000-12-21
PE20010430A1 (es) 2001-04-14
TR200103607T2 (tr) 2002-10-21
AU4944300A (en) 2001-01-02
TNSN00133A1 (fr) 2002-05-30
WO2000077018A2 (fr) 2000-12-21
DZ3168A1 (fr) 2000-12-21
UY26204A1 (es) 2001-01-31
NO20016109L (no) 2002-02-15
AP2001002361A0 (en) 2001-12-31
HUP0203419A2 (hu) 2003-02-28
ZA200110208B (en) 2002-12-12
PL354367A1 (en) 2004-01-12
GB9913932D0 (en) 1999-08-18
PA8497001A1 (es) 2001-12-14
EE200100681A (et) 2003-04-15
GT200000096A (es) 2001-12-06
EA200101203A1 (ru) 2002-06-27
MA26799A1 (fr) 2004-12-20
NO20016109D0 (no) 2001-12-14
CZ20014397A3 (cs) 2003-04-16

Similar Documents

Publication Publication Date Title
CA2379786C (fr) Derives de purine
AU771531B2 (en) Purine derivatives
CA2414018C (fr) Derives de 2-aminocarbonyl-9h-purine
AP1372A (en) Purine derivatives.
AU768308B2 (en) Purine derivatives
US6525032B2 (en) Purine derivatives